Retatrutide is the next generation for the treatment of obesity and related metabolic diseases, such as type 2 diabetes. It acts as an agonist of multiple hormone receptors that regulate appetite and metabolism in the body. The primary goal of Retatrutide is to aid in weight loss by reducing appetite, increasing the feeling of satiety, and regulating glucose metabolism.

The mechanism of action of Retatrutide involves interaction with three hormones: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic peptide), and glucagon. These hormones play a key role in appetite control, insulin secretion, and fat breakdown.

The drug is part of a new generation of weight-loss medications being developed with the aim of providing more effective and long-lasting solutions for weight management and metabolic diseases.